ATAI Life Sciences

IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

Founded in 2014, Beckley Psytech is a UK-based company dedicated to developing psychedelic medicines for treating mental health disorders. It focuses on rigorous scientific research and clinical-stage drug development, aiming to provide innovative treatments for conditions like depression and anxiety.

Founded in 2014, Beckley Psytech is a UK-based company dedicated to developing psychedelic medicines for treating mental health disorders. It focuses on rigorous scientific research and clinical-stage drug development, aiming to provide innovative treatments for conditions like depression and anxiety.

IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

Psyber is a company focused on creating innovative interventions for various mental health disorders through brain-computer interface (BCI)-enabled digital therapeutics. By integrating BCI technology with psychedelics, Psyber develops devices that monitor electrical activity in the brain, allowing for real-time analysis of emotional, behavioral, and mental states. This approach aims to empower patients who are prescribed medication, facilitating changes in their feelings and behaviors to enhance their overall quality of life. Through its advanced therapeutic solutions, Psyber seeks to address the growing need for effective mental health treatment options.

IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

Recognify Life Sciences is a biotechnology company focused on developing innovative treatments for cognitive impairment associated with schizophrenia. The company aims to transform the management of cognitive deficits by creating pharmaceutical therapies that modulate the excitatory and inhibitory balance in the brain. This approach is designed to enhance learning and memory, providing healthcare providers with new options to address cognitive impairment not only in schizophrenia but also in conditions such as Alzheimer's and other neurodegenerative and neurocognitive diseases. Recognify Life Sciences is dedicated to improving the quality of life for individuals affected by these challenging disorders.

COMPASS Pathways is a UK-based mental health care company dedicated to accelerating patient access to innovative treatments for mental health challenges. The company focuses on developing psilocybin therapy, administered in conjunction with psychological support, for patients with treatment-resistant depression who have not responded to conventional treatments.

Innoplexus develops AI and blockchain-based products to help enterprises gain insights from structured and unstructured data. Its life science solutions include Ontosight for real-time pharmaceutical industry insights, Ontosight Xplore for pre-clinical drug discovery, Clinical Trial Prediction Engine, and a Data as a Service platform. It also offers financial services AI products like RegI for risk management, and academic AI products such as Ontosight Academic. Serving clients in pharma, finance, academia, and more, Innoplexus aims to empower continuous decision-making through broader, deeper, and faster insights.

Perception Neuroscience is a biopharmaceutical company dedicated to creating innovative therapies for neuropsychiatric conditions. The company's primary focus is on developing arketamine, an NMDA antagonist designed to offer effective treatment for serious psychiatric disorders. Arketamine has shown promise for its rapid-acting antidepressant properties and potential anti-suicidal effects, positioning the company at the forefront of advancing mental health treatment solutions.